VE416 is a rationally defined bacterial consortium candidate being developed for the treatment of allergic disease including peanut allergy. VE416 consists of clonal human commensal bacteria strains selected for their ability to suppress allergic responses and manufactured under GMP conditions. Vedanta will be initiating a clinical study in patients with peanut allergy in 2019 to evaluate VE416 as a monotherapy, and in combination with oral immunotherapy.